Financhill
Sell
26

UTMD Quote, Financials, Valuation and Earnings

Last price:
$53.50
Seasonality move :
4.27%
Day range:
$53.50 - $54.10
52-week range:
$51.26 - $77.33
Dividend yield:
2.26%
P/E ratio:
14.20x
P/S ratio:
4.68x
P/B ratio:
1.50x
Volume:
9.4K
Avg. volume:
18.5K
1-year change:
-22.82%
Market cap:
$175.9M
Revenue:
$40.9M
EPS (TTM):
$3.78

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
UTMD
Utah Medical Products
-- -- -- -- --
ARMP
Armata Pharmaceuticals
$1.4M -$0.50 -- -44.93% $7.00
CATX
Perspective Therapeutics
$123.9K -$0.35 -- -35.77% $14.3929
ELMD
Electromed
$16.4M -- 13.91% -- $37.00
PLX
Protalix BioTherapeutics
$23.9M -- 476.31% -- $14.50
XTNT
Xtant Medical Holdings
$31.1M -$0.01 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
UTMD
Utah Medical Products
$53.60 -- $175.9M 14.20x $0.31 2.26% 4.68x
ARMP
Armata Pharmaceuticals
$1.29 $7.00 $46.7M -- $0.00 0% 467.58x
CATX
Perspective Therapeutics
$2.3500 $14.3929 $174M -- $0.00 0% 15.21x
ELMD
Electromed
$22.27 $37.00 $190.6M 29.69x $0.00 0% 3.34x
PLX
Protalix BioTherapeutics
$1.72 $14.50 $134.2M 57.33x $0.00 0% 2.67x
XTNT
Xtant Medical Holdings
$0.50 $1.75 $70.2M -- $0.00 0% 0.58x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
UTMD
Utah Medical Products
-- 0.848 -- 20.18x
ARMP
Armata Pharmaceuticals
-- 2.116 -- --
CATX
Perspective Therapeutics
-- -1.032 -- --
ELMD
Electromed
-- 2.545 -- 4.68x
PLX
Protalix BioTherapeutics
-- 1.057 -- 1.47x
XTNT
Xtant Medical Holdings
44.29% -0.806 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
UTMD
Utah Medical Products
$5.5M $3.2M 10.61% 10.61% 32.48% $2.9M
ARMP
Armata Pharmaceuticals
-- -$10.5M -- -- -- -$7.9M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
PLX
Protalix BioTherapeutics
$14.3M $7.2M 6.41% 8.75% 40.19% $3.6M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Utah Medical Products vs. Competitors

  • Which has Higher Returns UTMD or ARMP?

    Armata Pharmaceuticals has a net margin of 31.32% compared to Utah Medical Products's net margin of --. Utah Medical Products's return on equity of 10.61% beat Armata Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    UTMD
    Utah Medical Products
    57.03% $0.92 $117M
    ARMP
    Armata Pharmaceuticals
    -- -$0.23 --
  • What do Analysts Say About UTMD or ARMP?

    Utah Medical Products has a consensus price target of --, signalling downside risk potential of --. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 442.64%. Given that Armata Pharmaceuticals has higher upside potential than Utah Medical Products, analysts believe Armata Pharmaceuticals is more attractive than Utah Medical Products.

    Company Buy Ratings Hold Ratings Sell Ratings
    UTMD
    Utah Medical Products
    0 0 0
    ARMP
    Armata Pharmaceuticals
    0 0 0
  • Is UTMD or ARMP More Risky?

    Utah Medical Products has a beta of 0.300, which suggesting that the stock is 69.99% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.252%.

  • Which is a Better Dividend Stock UTMD or ARMP?

    Utah Medical Products has a quarterly dividend of $0.31 per share corresponding to a yield of 2.26%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products pays 30.71% of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend. Utah Medical Products's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios UTMD or ARMP?

    Utah Medical Products quarterly revenues are $9.7M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Utah Medical Products's net income of $3M is higher than Armata Pharmaceuticals's net income of $2.6M. Notably, Utah Medical Products's price-to-earnings ratio is 14.20x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products is 4.68x versus 467.58x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    UTMD
    Utah Medical Products
    4.68x 14.20x $9.7M $3M
    ARMP
    Armata Pharmaceuticals
    467.58x -- -- $2.6M
  • Which has Higher Returns UTMD or CATX?

    Perspective Therapeutics has a net margin of 31.32% compared to Utah Medical Products's net margin of --. Utah Medical Products's return on equity of 10.61% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    UTMD
    Utah Medical Products
    57.03% $0.92 $117M
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About UTMD or CATX?

    Utah Medical Products has a consensus price target of --, signalling downside risk potential of --. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 512.46%. Given that Perspective Therapeutics has higher upside potential than Utah Medical Products, analysts believe Perspective Therapeutics is more attractive than Utah Medical Products.

    Company Buy Ratings Hold Ratings Sell Ratings
    UTMD
    Utah Medical Products
    0 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is UTMD or CATX More Risky?

    Utah Medical Products has a beta of 0.300, which suggesting that the stock is 69.99% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock UTMD or CATX?

    Utah Medical Products has a quarterly dividend of $0.31 per share corresponding to a yield of 2.26%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products pays 30.71% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend. Utah Medical Products's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios UTMD or CATX?

    Utah Medical Products quarterly revenues are $9.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Utah Medical Products's net income of $3M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Utah Medical Products's price-to-earnings ratio is 14.20x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products is 4.68x versus 15.21x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    UTMD
    Utah Medical Products
    4.68x 14.20x $9.7M $3M
    CATX
    Perspective Therapeutics
    15.21x -- -- -$40.2M
  • Which has Higher Returns UTMD or ELMD?

    Electromed has a net margin of 31.32% compared to Utah Medical Products's net margin of 12.11%. Utah Medical Products's return on equity of 10.61% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    UTMD
    Utah Medical Products
    57.03% $0.92 $117M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About UTMD or ELMD?

    Utah Medical Products has a consensus price target of --, signalling downside risk potential of --. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 66.14%. Given that Electromed has higher upside potential than Utah Medical Products, analysts believe Electromed is more attractive than Utah Medical Products.

    Company Buy Ratings Hold Ratings Sell Ratings
    UTMD
    Utah Medical Products
    0 0 0
    ELMD
    Electromed
    2 0 0
  • Is UTMD or ELMD More Risky?

    Utah Medical Products has a beta of 0.300, which suggesting that the stock is 69.99% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

  • Which is a Better Dividend Stock UTMD or ELMD?

    Utah Medical Products has a quarterly dividend of $0.31 per share corresponding to a yield of 2.26%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products pays 30.71% of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend. Utah Medical Products's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios UTMD or ELMD?

    Utah Medical Products quarterly revenues are $9.7M, which are smaller than Electromed quarterly revenues of $16.3M. Utah Medical Products's net income of $3M is higher than Electromed's net income of $2M. Notably, Utah Medical Products's price-to-earnings ratio is 14.20x while Electromed's PE ratio is 29.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products is 4.68x versus 3.34x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    UTMD
    Utah Medical Products
    4.68x 14.20x $9.7M $3M
    ELMD
    Electromed
    3.34x 29.69x $16.3M $2M
  • Which has Higher Returns UTMD or PLX?

    Protalix BioTherapeutics has a net margin of 31.32% compared to Utah Medical Products's net margin of 35.65%. Utah Medical Products's return on equity of 10.61% beat Protalix BioTherapeutics's return on equity of 8.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    UTMD
    Utah Medical Products
    57.03% $0.92 $117M
    PLX
    Protalix BioTherapeutics
    78.67% $0.09 $43.2M
  • What do Analysts Say About UTMD or PLX?

    Utah Medical Products has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 743.02%. Given that Protalix BioTherapeutics has higher upside potential than Utah Medical Products, analysts believe Protalix BioTherapeutics is more attractive than Utah Medical Products.

    Company Buy Ratings Hold Ratings Sell Ratings
    UTMD
    Utah Medical Products
    0 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is UTMD or PLX More Risky?

    Utah Medical Products has a beta of 0.300, which suggesting that the stock is 69.99% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

  • Which is a Better Dividend Stock UTMD or PLX?

    Utah Medical Products has a quarterly dividend of $0.31 per share corresponding to a yield of 2.26%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products pays 30.71% of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend. Utah Medical Products's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios UTMD or PLX?

    Utah Medical Products quarterly revenues are $9.7M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Utah Medical Products's net income of $3M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Utah Medical Products's price-to-earnings ratio is 14.20x while Protalix BioTherapeutics's PE ratio is 57.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products is 4.68x versus 2.67x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    UTMD
    Utah Medical Products
    4.68x 14.20x $9.7M $3M
    PLX
    Protalix BioTherapeutics
    2.67x 57.33x $18.2M $6.5M
  • Which has Higher Returns UTMD or XTNT?

    Xtant Medical Holdings has a net margin of 31.32% compared to Utah Medical Products's net margin of -10.04%. Utah Medical Products's return on equity of 10.61% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    UTMD
    Utah Medical Products
    57.03% $0.92 $117M
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About UTMD or XTNT?

    Utah Medical Products has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 246.78%. Given that Xtant Medical Holdings has higher upside potential than Utah Medical Products, analysts believe Xtant Medical Holdings is more attractive than Utah Medical Products.

    Company Buy Ratings Hold Ratings Sell Ratings
    UTMD
    Utah Medical Products
    0 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is UTMD or XTNT More Risky?

    Utah Medical Products has a beta of 0.300, which suggesting that the stock is 69.99% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

  • Which is a Better Dividend Stock UTMD or XTNT?

    Utah Medical Products has a quarterly dividend of $0.31 per share corresponding to a yield of 2.26%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products pays 30.71% of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend. Utah Medical Products's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios UTMD or XTNT?

    Utah Medical Products quarterly revenues are $9.7M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Utah Medical Products's net income of $3M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Utah Medical Products's price-to-earnings ratio is 14.20x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products is 4.68x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    UTMD
    Utah Medical Products
    4.68x 14.20x $9.7M $3M
    XTNT
    Xtant Medical Holdings
    0.58x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Are We Heading Toward a Recession?
Are We Heading Toward a Recession?

Fears of a recession in 2025 grew at the end…

3 Recession-Proof ETFs to Invest in Now
3 Recession-Proof ETFs to Invest in Now

The U.S. gross domestic product (GDP) contracted 0.3% during the…

Is Butterfly Network the Best Small-Cap Stock?
Is Butterfly Network the Best Small-Cap Stock?

Brought to public trading by an SPAC merger in early…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock